Interventional Cardiology

Coronary Therapies

The medical device industry’s most complete portfolio of PCI products

Together we can strengthen quality outcomes, increase operational efficiencies, and improve financial health in your cardiovascular service line (CVSL).

30%

Of all U.S. PCI patients present with calcium

20%

Of all U.S. PCIs are complex

~60%

Higher reimbursement for complex PCI vs. standard PCI**

If complex PCI is a focus, we can help. As the market leader in Interventional Cardiology, Boston Scientific brings the most comprehensive portfolio of PCI products, education programs, and healthcare solutions and partnerships. Work with us to:


The market leader in coronary therapies

SYNERGY™ Bioabsorbable Polymer (BP) Stent Systems

Putting the patient first, we offer all the products, programs and solutions designed to help your CVSL strengthen quality outcomes, increase operational efficiencies, and improve financial health.

Leading on Studying Short DAPT

The SYNERGY BP Stent is indicated for use in high bleeding risk patients with short DAPT labeling. Boston Scientific is leading the way in supporting short DAPT studies with the SYNERGY BP Stent in a variety of patient populations and DAPT durations.

.0% ST

0-month DAPT
ASET Trial
1

3 months post PCI

.0% ST

1 month DAPT
SENIOR Trial
2

From 1-12 months

.9% ST

1 month DAPT
POEM Trial
3

At 1 year

.2% ST

3 month DAPT
EVOLVE Short DAPT
4

From 3-15 months


A full portfolio built for modern PCI

Tools to diagnose, prep, treat, and validate because no two patients are the same.

PCI Guidance

AVVIGO™
Guidance System II

COMET II™
FFR Pressure Guidewire

OPTICROSS™ HD
Imaging Catheters

Complex PCI

ROTAPRO™
Rotational Atherectomy System

AVVIGO™
Guidance System II

SENTAI™
Guidewires

Drug-Eluting Therapies

SYNERGY™ XD Stent System
Equipped with an innovative delivery system designed to make optimal healing even more deliverable

SYNERGY™ XD 48 mm Stent System
Designed to address the unique needs of long lesions

SYNERGY MEGATRON™ Stent System
Purpose-built DES for large proximal vessels


Coding and payment guides

Find additional information on coding, payment guides, and reimbursement information for inpatient, outpatient, office, and ASC settings.

Practical solutions for complex challenges

Boston Scientific is offering a growing selection of offerings specifically tailored to propel your cardiovascular business forward.

Contact Us

Get in touch with a sales representative to discuss how our portfolio of product and solutions can deliver measurable outcomes in the cardiovascular service line.


References:

**CY2021 CMS national base rate is $16,064 for APC 5194 vs. $10,043 for APC 5193. Actual rates will vary geographically and/or by individual facility
1. Presented by Pedro Lemos, MD at TCT2019
2. Kogame N, et al. J Am Coll Cardiol Intv. 2020;13:2251-62. DOI: 10.1016/j.jcin.2020.06.023
3. Presented by Giulio Stefanini, MD at EuroPCR 2021. This study evaluated the safety of the SYNERGY BP Stent with 1-month DAPT in high bleeding risk (HBR) patients
4. Pivato C.A., et al. J Am Heart Assoc. 2022;11:e023454. DOI: 10.1161/JAHA.121.023454
5. The SYNERGY BP Stent HBR indication is supported by the EVOLVE Short DAPT data. The HBR indication excludes SYNERGY XD 48 mm